Why the study?
Do gender and race impact the use of antithrombotic therapy at discharge in patients with stroke/TIA?
Do gender and race impact the use of antithrombotic therapy at discharge in patients with stroke/TIA?
In a Medicare population with stroke/TIA, there were no significant disparities by sex or race in the prescription of antithrombotic therapy at discharge.
No adjusted race or sex differences in antithrombotic discharge prescriptions support equitable patterns in this Medicare cohort; leaves open confirmation in broader populations.
The authors examined the relationships between sex and race and antithrombotics prescribed at discharge in the Michigan Medicare population using retrospective medical record abstraction (n = 2,715) for the period January 1, 2001, to June 30, 2001. There were no differences in the use of antithrombotics at discharge by race or sex and no differences in the prescribing of aspirin, warfarin, aspirin/extended release dipyridamole, or clopidogrel by race or sex after adjustment for confounders.
No takes yet. Share an insight, caveat, or question.
Lisabeth et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: